Journal Mobile Options
Table of Contents
Vol. 24, No. 5, 2007
Issue release date: October 2007
Dement Geriatr Cogn Disord 2007;24:348–362

Neuroimaging and APOE Genotype: A Systematic Qualitative Review

Cherbuin N. · Leach L.S. · Christensen H. · Anstey K.J.
Centre for Mental Health Research, Australian National University, Canberra, Australia

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Apolipoprotein E (APOE) is the major genetic risk factor for late-onset Alzheimer’s disease (AD) and has also been implicated in cardiovascular disease, cognitive decline and cognitive changes in healthy ageing. The aim of this paper is to systematically review and critically assess the association between the APOE genotype and structural/functional cerebral changes as evidenced by brain imaging studies. A second aim is to determine whether these observed associations between APOE and the brain reflect changes which are consistent with the progression of AD neurodegenerative changes described in Braak stages. A search of Pubmed, Psycinfo, and Web of Science databases identified 64 articles available for qualitative review. The review found that presence of the APOE ε4 allele is associated with (1) hippocampal, amygdalar and entorhinal cortex atrophy, (2) increased brain atrophy, (3) increased white matter hyperintensity volumes and (4) altered cerebral blood flow and glucose metabolism patterns. It is possible that there are critical age ranges when these effects are evident and that the APOE ε2 genotype might present a risk. We conclude that structural brain change is associated with the APOE genotype and that it is more salient in younger ageing individuals.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Blacker D, et al: ApoE-4 and age at onset of Alzheimer’s disease: The NIMH genetics initiative. Neurology 1997;48:139–147.
  2. Gong J-S, et al: Apolipoprotein E (ApoE) isoform-dependent lipid release from astrocytes prepared from human ApoE3 and ApoE4 knock-in mice. J Biol Chem 2002;277:29919–29926.
  3. Martins CA, et al: APOE alleles predict the rate of cognitive decline in Alzheimer disease: a nonlinear model. Neurology 2005;65:1888–1893.
  4. Fazekas F, et al: The impact of our genes: consequences of the apolipoprotein E polymorphism in Alzheimer disease and multiple sclerosis. J Neurol Sci 2006;245:35–39.
  5. Horsburgh K, et al: The role of apolipoprotein E in Alzheimer’s disease, acute brain injury and cerebrovascular disease: evidence of common mechanisms and utility of animal models. Neurobiol Aging 2000;21:245–255.
  6. Smith JD: Apolipoproteins and aging: emerging mechanisms. Ageing Res Rev 2002;1:345–365.
  7. Savitz J, et al: Apolipoprotein E variants and cognition in healthy individuals: a critical opinion. Brain Res Rev 2006;51:125–135.
  8. Jorm AF, et al: APOE genotype and cognitive functioning in a large age-stratified population sample. Neuropsychology 2007;21:1–8.
  9. Teter B: Life-span influences of apoE4 on CNS function. Neurobiol Aging 2006;28:693–703.
  10. Braak H, et al: Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol (Berl) 2006;112:389–404.
  11. Braak H, et al: Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl) 1991;82:239–259.
  12. Ohm TG, et al: Close-meshed prevalence rates of different stages as a tool to uncover the rate of Alzheimer’s disease-related neurofibrillary changes. Neuroscience 1995;64:209–217.
  13. Ohm TG, et al: Apolipoprotein E isoforms and the development of low and high Braak stages of Alzheimer’s disease-related lesions. Acta Neuropathol 1999;98:273–280.
  14. Bigler ED, et al: Dementia, quantitative neuroimaging, and apolipoprotein E genotype. Am J Neuroradiol 2000;21:1857–1867.
  15. Hashimoto M, et al: Apolipoprotein E epsilon 4 and the pattern of regional brain atrophy in Alzheimer’s disease. Neurology 2001;57:1461–1466.
  16. Lehtovirta M, et al: Volumes of hippocampus, amygdala and frontal lobe in Alzheimer patients with different apolipoprotein E genotypes. Neuroscience 1995;67:65–72.
  17. Mori E, et al: Accelerated hippocampal atrophy in Alzheimer’s disease with apolipoprotein E epsilon 4 allele. Ann Neurol 2002;51:209–214.
  18. Lemaitre H, et al: No epsilon 4 gene dose effect on hippocampal atrophy in a large MRI database of healthy elderly subjects. Neuroimage 2005;24:1205–1213.
  19. Yamaguchi S, et al: Temporal progression of hippocampal atrophy and apolipoprotein E gene in Alzheimer’s disease. J Am Geriatr Soc 1996;44:216–217.
  20. Fleisher A, et al: Sex, apolipoprotein E epsilon 4 status, and hippocampal volume in mild cognitive impairment. Arch Neurol 2005;62:953–957.
  21. Lind J, et al: Reduced hippocampal volume in non-demented carriers of the apolipoprotein E epsilon 4: relation to chronological age and recognition memory. Neurosci Lett 2006;396:23–27.
  22. Soininen H, et al: Decreased hippocampal volume asymmetry on MRIs in nondemented elderly subjects carrying the apolipoprotein E epsilon 4 allele. Neurology 1995;45:391–392.
  23. Tohgi H, et al: Reduced size of right hippocampus in 39- to 80-year-old normal subjects carrying the apolipoprotein E epsilon 4 allele. Neurosci Lett 1997;236:21–24.
  24. Geroldi C, et al: Apolipoprotein E genotype and hippocampal asymmetry in Alzheimer’s disease: a volumetric MRI study. J Neurol Neurosurg Psychiatry 2000;68:93–96.
  25. Serra-Grabulosa JM, et al: Apolipoproteins E and C1 and brain morphology in memory impaired elders. Neurogenetics 2003;4:141–146.
  26. Talbot C, et al: Protection against Alzheimer’s disease with apoE ε2. Lancet 1994;343:1432–1433.
  27. Kaur M, et al: APOE2 and consanguinity: a risky combination for Alzheimer’s disease. J Alzheimers Dis 2005;8:293–297.
  28. van Duijn CM, et al: The apolipoprotein E epsilon 2 allele is associated with an increased risk of early-onset Alzheimer’s disease and a reduced survival. Ann Neurol 1995;37:605–610.
  29. den Heijer T, et al: Hippocampal, amygdalar, and global brain atrophy in different apolipoprotein E genotypes. Neurology 2002;59:746–748.
  30. Barboriak DP, et al: Hippocampal sulcal cavities on MRI: relationship to age and apolipoprotein E genotype. Neurology 2000;54:2150–2153.
  31. Du AT, et al: Age effects on atrophy rates of entorhinal cortex and hippocampus. Neurobiol Aging 2006;27:733–740.
  32. Geroldi C, et al: APOE-epsilon 4 is associated with less frontal and more medial temporal lobe atrophy in AD. Neurology 1999;53:1825–1832.
  33. Juottonen K, et al: Major decrease in the volume of the entorhinal cortex in patients with Alzheimer’s disease carrying the apolipoprotein E epsilon 4 allele. J Neurol Neurosurg Psychiatry 1998;65:322–327.
  34. Barber R, et al: MRI volumetric study of dementia with Lewy bodies – A comparison with AD and vascular dementia. Neurology 2000;54:1304–1309.
  35. Enzinger C, et al: Risk factors for progression of brain atrophy in aging – Six-year follow-up of normal subjects. Neurology 2005;64:1704–1711.
  36. Yasuda M, et al: Apolipoprotein E epsilon 4 allele and whole brain atrophy in late-onset Alzheimer’s disease. Am J Psychiatry 1998;155:779–784.
  37. DeCarli C, et al: Impact of apolipoprotein E epsilon 4 and vascular disease on brain morphology in men from the NHLBI twin study. Stroke 1999;30:1548–1553.
  38. Carmelli D, et al: The joint effect of apolipoprotein E epsilon 4 and MRI findings on lower-extremity function and decline in cognitive function. J Gerontol Seri A Biol Sci Med Sci 2000;55:M103–M109.
  39. Boccardi M, et al: APOE and modulation of Alzheimer’s and frontotemporal dementia. Neurosci Lett 2004;356:167–170.
  40. Gunning-Dixon FM, et al: The cognitive correlates of white matter abnormalities in normal aging: a quantitative review. Neuropsychology 2000;14:224–232.
  41. Wahlund LO, et al: White matter hyperintensities in dementia: does it matter? Magn Reson Imaging 1994;12:387–394.
  42. Hogh P, et al: Single photon emission computed tomography and apolipoprotein E in Alzheimer’s disease: impact of the epsilon 4 allele on regional cerebral blood flow. J Geriatr Psychiatry Neurol 2001;14:42–51.
  43. Lehtovirta M, et al: Longitudinal SPECT study in Alzheimer’s disease: relation to apolipoprotein E polymorphism. J Neurol Neurosurg Psychiatry 1998;64:742–746.
  44. Lehtovirta M, et al: SPECT and MRI analysis in Alzheimer’s disease: relation to apolipoprotein E epsilon 4 allele. J Neurol Neurosurg Psychiatry 1996;60:644–649.
  45. van Dyck CH, et al: Absence of an apolipoprotein E epsilon 4 allele is associated with increased parietal regional cerebral blood flow asymmetry in Alzheimer disease. Arch Neurol 1998;55:1460–1466.
  46. Reiman EM, et al: From The cover: correlations between apolipoprotein E ε4 gene dose and brain-imaging measurements of regional hypometabolism. PNAS 2005;102:8299–8302.
  47. Small GW, et al: Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. JAMA 1995;273:942–947.
  48. Reiman EM, et al: Preclinical evidence of Alzheimer’s disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med 1996;334:752–758.
  49. Lee KU, et al: Influence of the apolipoprotein E type 4 allele on cerebral glucose metabolism in Alzheimer’s disease patients. J Neuropsychiatry Clin Neurosci 2003;15:78–83.
  50. Hirono N, et al: The effect of APOE epsilon 4 allele on cerebral glucose metabolism in AD is a function of age at onset. Neurology 2002;58:743–750.
  51. Greenwood PM, et al: Genetics and visual attention: selective deficits in healthy adult carriers of the epsilon 4 allele of the apolipoprotein E gene. Proc Natl Acad Sci USA 2000;97:11661–11666.
  52. Greenwood PM, et al: Scaling of visuospatial attention undergoes differential longitudinal change as a function of APOE genotype prior to old age: results from the NIMH BIOCARD study. Neuropsychology 2005;19:830–840.
  53. Dik MG, et al: Memory complaints and APOE-epsilon 4 accelerate cognitive decline in cognitively normal elderly. Neurology 2001;57:2217–2222.
  54. van Dijk EJ, et al: Plasma amyloid beta, apolipoprotein E, lacunar infarcts, and white matter lesions. Ann Neurol 2004;55:570–575.
  55. Skoog I, et al: Apolipoprotein E in cerebrospinal fluid in 85-year-old subjects. Relation to dementia, apolipoprotein E polymorphism, cerebral atrophy, and white matter lesions. Arch Neurol 1997;54:267–272.
  56. Pesaresi M, et al: Plasma levels of beta-amyloid (1–42) in Alzheimer’s disease and mild cognitive impairment. Neurobiol Aging 2006;27:904–905.
  57. Russo C, et al: Opposite roles of apolipoprotein E in normal brains and in Alzheimer’s disease. PNAS 1998;95:15598–15602.
  58. Thompson PM, et al: Dynamics of gray matter loss in Alzheimer’s disease. J Neurosci 2003;23:994–1005.
  59. Scarmeas N, et al: Altered PET functional brain responses in cognitively intact elderly persons at risk for Alzheimer disease (carriers of the epsilon 4 allele). Am J Geriatr Psychiatry 2004;12:596–605.
  60. den Heijer T, et al: Alcohol intake in relation to brain magnetic resonance imaging findings in older persons without dementia. Am J Clin Nutr 2004;80:992–997.
  61. Farlow MR, et al: Impact of APOE in mild cognitive impairment. Neurology 2004;63:1898–1901.
  62. Wang PN, et al: The MCI study in Taiwan. Acta Neurol Taiwan 2006;15:66–68.

    External Resources

  63. Reiman EM, et al: Hippocampal volumes in cognitively normal persons at genetic risk for Alzheimer’s disease. Ann Neurol 1998;44:288–291.
  64. Schmidt H, et al: Apolipoprotein E ε4 allele in the normal elderly: neuropsychologic and brain MRI correlates. Clin Genet 1996;50:293–299.
  65. Basso M, et al: Apolipoprotein E epsilon 4 is associated with atrophy of the amygdala in Alzheimer’s disease. Neurobiol Aging 2006;27:1416–1424.
  66. Jack CR, et al: Rate of medial temporal lobe atrophy in typical aging and Alzheimer’s disease. Neurology 1998;51:993–999.
  67. Jack CR, et al: Hippocampal atrophy and apolipoprotein E genotype are independently associated with Alzheimer’s disease. Ann Neurol 1998;43:303–310.
  68. Espeseth T, et al: Interactive effects of APOE and CHRNA4 on attention and white matter volume in healthy middle-aged and older adults. Cogn Affect Behav Neurosci 2006;6:31–43.

    External Resources

  69. Pennanen C, et al: The effect of apolipoprotein polymorphism on brain in mild cognitive impairment: a voxel-based morphometric study. Dementia Geriatr Cogn Disord 2006;22:60–66.
  70. Wishart HA, et al: Regional brain atrophy in cognitively intact adults with a single APOE epsilon 4 allele. Neurology 2006;67:1221–1224.
  71. Tanaka S, et al: Inferior temporal lobe atrophy and APOE genotypes in Alzheimer’s disease – X-ray computed tomography, magnetic resonance imaging and Xe-133 SPECT studies. Dementia Geriatr Cogn Disord 1998;9:90–98.
  72. Wahlund LO, et al: Inheritance of the ApoE epsilon 4 allele increases the rate of brain atrophy in dementia patients. Dementia Geriatr Cogn Disord 1999;10:262–268.
  73. Yoshida S, et al: Clinical features and alterations in the inferior horn sizes in lateral ventricle in Alzheimer’s patients with different ApoE genotype in Japanese population. Progr Neuropsychopharmacol Biol Psychiatry 2001;25:1377–1384.
  74. de Leeuw FE, et al: Interaction between hypertension, apoE, and cerebral white matter lesions. Stroke 2004;35:1057–1060.
  75. Steffens DC, et al: Apolipoprotein E genotype and subcortical vascular lesions in older depressed patients and control subjects. Biol Psychiatry 2003;54:674–681.
  76. Schmidt R, et al: Apolipoprotein E polymorphism and silent microangiopathy-related cerebral damage: results of the Austrian Stroke Prevention Study. Stroke 1997;28:951–956.
  77. Bronge L, et al: White matter lesions in Alzheimer patients are influenced by apolipoprotein E genotype. Dementia Geriatr Cogn Disord 1999;10:89–96.
  78. Amar K, et al: Are genetic factors important in the aetiology of leukoaraiosis? Results from a memory clinic population. Int J Geriatr Psychiatry 1998;13:585–590.
  79. Barber R, et al: Apolipoprotein E epsilon 4 allele, temporal lobe atrophy, and white matter lesions in late-life dementias. Arch Neurol 1999;56:961–965.
  80. Bigler ED, et al: Dementia, asymmetry of temporal lobe structures, and apolipoprotein E genotype: relationships to cerebral atrophy and neuropsychological impairment. J Int Neuropsychol Soc 2002;8:925–933.
  81. Bracco L, et al: Alzheimer’s disease: role of size and location of white matter changes in determining cognitive deficits. Dementia Geriatr Cogn Disord 2005;20:358–366.
  82. Doody RS, et al: Does APO epsilon 4 correlate with MRI changes in Alzheimer’s disease? J Neurol Neurosurg Psychiatry 2000;69:668–671.
  83. Gurol ME, et al: Plasma β-amyloid and white matter lesions in AD, MCI, and cerebral amyloid angiopathy. Neurology 2006;66:23–29.
  84. Hirono N, et al: Effect of the apolipoprotein E epsilon 4 allele on white matter hyperintensities in dementia. Stroke 2000;31:1263–1268.
  85. Borroni B, et al: Functional correlates of apolipoprotein E genotype in frontotemporal lobar degeneration. BMC Neurol 2006;6:31.
  86. Sun ZW, et al: Decreased cerebral blood flow velocity in apolipoprotein E epsilon 4 allele carriers with mild cognitive impairment. Eur J Neurol 2007;14:150–155.
  87. Drzezga A, et al: Cerebral glucose metabolism in patients with AD and different APOE genotypes. Neurology 2005;64:102–107.
  88. Mosconi L, et al: Metabolic interaction between ApoE genotype and onset age in Alzheimer’s disease: implications for brain reserve. J Neurol Neurosurg Psychiatry 2005;76:15–23.
  89. Mosconi L, et al: MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET. Neurology 2004;63:2332–2340.
  90. Mosconi L, et al: Brain metabolic decreases related to the dose of the ApoE ε4 allele in Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2004;75:370–376.
  91. Mosconi L, et al: Age and ApoE genotype interaction in Alzheimer’s disease: an FDG-PET study. Psychiatry Res Neuroimag 2004;130:141–151.
  92. Corder EH, et al: No difference in cerebral glucose metabolism in patients with Alzheimer disease and differing apolipoprotein E genotypes. Arch Neurol 1997;54:273–277.
  93. Hirono N, et al: Lack of association of apolipoprotein E epsilon 4 allele dose with cerebral glucose metabolism in Alzheimer disease. Alzheimer Dis Assoc Disord 1998;12:362–367.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50